Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
J Card Fail. 2011 Jan;17(1):24-30. doi: 10.1016/j.cardfail.2010.08.007.
Resistin is a pro-inflammatory signaling molecule that is thought to contribute to atherosclerosis. We sought to evaluate whether resistin is predictive of worse cardiovascular outcomes among ambulatory patients with stable coronary heart disease (CHD).
We measured baseline serum resistin in 980 participants with documented CHD. After a mean follow-up of 6.1 (range, 0.1 to 9.0) years, 358 (36.5%) were hospitalized for myocardial infarction or heart failure or had died. As compared with participants who had resistin levels in the lowest quartile, those with resistin levels in the highest quartile were at an increased risk of heart failure (hazard ratio [HR], 2.06; 95% confidence interval [CI], 1.26-3.39) and death (HR, 1.56; 95% CI, 1.11-2.18), adjusted for age, sex, and race. Further adjustments for obesity, hypertension, insulin resistance, dyslipidemia, and renal dysfunction eliminated these associations. Resistin levels were not associated with an increased risk of non-fatal myocardial infarction (unadjusted HR, 1.18; 95% CI, 0.68-2.05).
Elevated serum resistin is associated with higher rates of mortality and hospitalization for heart failure. However, this appears to be explained by the association of resistin with traditional measures of cardiovascular risk. Thus, serum resistin does not add prognostic information among high-risk persons with established CHD.
抵抗素是一种促炎信号分子，被认为与动脉粥样硬化有关。我们试图评估在有稳定冠心病（CHD）的门诊患者中，抵抗素是否可预测更差的心血管结局。
我们在 980 名有记录的 CHD 患者中测量了基线血清抵抗素。在平均 6.1 年（范围，0.1 至 9.0 年）的随访后，358 名（36.5%）因心肌梗死或心力衰竭住院或死亡。与抵抗素水平处于最低四分位数的参与者相比，处于最高四分位数的参与者心力衰竭（风险比[HR]，2.06；95%置信区间[CI]，1.26-3.39）和死亡（HR，1.56；95%CI，1.11-2.18）的风险增加，调整了年龄、性别和种族。进一步调整肥胖、高血压、胰岛素抵抗、血脂异常和肾功能不全消除了这些关联。抵抗素水平与非致命性心肌梗死的风险增加无关（未调整的 HR，1.18；95%CI，0.68-2.05）。
血清抵抗素水平升高与死亡率和心力衰竭住院率升高相关。然而，这似乎与抵抗素与心血管风险的传统测量指标有关。因此，在有既定 CHD 的高危人群中，血清抵抗素并不能提供预后信息。
